Company Overview and News

 
Hydro One and Avista extend their merger End Date

2018-09-19 globenewswire
TORONTO and SPOKANE, Wash., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Hydro One Limited (“Hydro One”) (TSX: H) and Avista Corporation (“Avista”) (NYSE: AVA) announced today that Hydro One has received a notice from Avista to extend the transaction End Date to March 29, 2019, as provided for in the merger agreement.
H AVA HRNNF

 
HRNNF / Hydro One Ltd 6-K (Current Report of Foreign Issuer)

2018-09-07 sec.gov
6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
HRNNF

 
HRNNF / Hydro One Ltd RW

2018-09-05 sec.gov
RW Hydro One Limited 483 Bay Street South Tower, 8th Floor Toronto, Ontario, Canada M5G 2P5 September 5, 2018 VIA EDG
HRNNF

 
HRNNF / Hydro One Ltd 6-K (Current Report of Foreign Issuer)

2018-09-04 sec.gov
6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
HRNNF

 
Avista Requests Natural Gas Price Decrease for Idaho Customers in Annual Natural Gas Cost Adjustment Filing

2018-08-27 globenewswire
SPOKANE, Wash., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Avista (NYSE: AVA) today filed its Purchased Gas Cost Adjustment (PGA) request with the Idaho Public Utilities Commission (IPUC or Commission) that, if approved, is designed to decrease overall natural gas revenues by approximately $0.6 million or 1.0 percent effective Nov. 1, 2018.
H AVA HRNNF

 
HRNNF / Hydro One Ltd 6-K (Current Report of Foreign Issuer)

2018-08-24 sec.gov
6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
HRNNF

 
Avista Makes Annual Price Adjustment Requests in Washington

2018-08-17 globenewswire
SPOKANE, Wash., Aug. 17, 2018 (GLOBE NEWSWIRE) -- Avista (NYSE: AVA) has made several annual rate adjustment filings with the Washington Utilities and Transportation Commission (UTC or Commission) that would, if approved, result in an overall decrease in electric and natural gas rates, effective Nov. 1, 2018.
H AVA HRNNF

100
Ontario’s Great Disrupter hits the cannabis market

2018-08-17 thestar - 3
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
STZ.B TWMJF H WEED STZ HRNNF CGC

97
Ontario’s Great Disrupter hits the cannabis market

2018-08-17 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
STZ.B TWMJF H WEED STZ HRNNF CGC

 
Hydro One given six months to trim executive pay

2018-08-15 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
H AVA HRNNF

 
Legislature’s heated summer session ends with battle lines drawn

2018-08-15 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
H HRNNF

 
Ontario Premier Doug Ford to make energy announcement

2018-08-15 cbc.ca
Ontario Premier Doug Ford and Energy Minister Greg Rickford are set to make an announcement in Toronto on Wednesday afternoon.
H HRNNF

 
HRNNF / Hydro One Ltd 6-K (Current Report of Foreign Issuer)

2018-08-15 sec.gov
6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
HRNNF

 
PRESS DIGEST-Canada-Aug 15

2018-08-15 reuters
Aug 15 (Reuters) - The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
H PTOAD HRNNF

 
HRNNF / Hydro One Ltd FORM 6-K (Current Report of Foreign Issuer)

2018-08-15 sec.gov
Form 6-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
HRNNF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...